Literature DB >> 14638409

Decrease in the hepatitis C virus (HCV) prevalence in hemodialysis patients in Spain: effect of time, initiating HCV prevalence studies and adoption of isolation measures.

Guillermina Barril1, Juan Antonio Traver.   

Abstract

The effectiveness of isolation measures to prevent hepatitis C virus (HCV) infection in hemodialysis units is a controversial issue. Strict adherence to the universal infection control precautions has been deemed adequate to prevent nosocomial transmission of HCV. Subsequently, however, select isolation measures, such as the clustering of HCV positive patients in a defined sector of the unit, have been adopted, specially for those units with a high HCV prevalence and when the personnel-patient ratio was such that it could involuntary favor the break of the universal precautions. In this Multicenter Spanish Study on HCV in Dialysis, the importance of both time and isolation measures led to a decrease of HCV prevalence. Time was the most important factor (although interacting with the isolation measures) and was independent of the initial HCV prevalence.

Entities:  

Mesh:

Year:  2003        PMID: 14638409     DOI: 10.1016/j.antiviral.2003.08.008

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  10 in total

Review 1.  Prevalence of hepatitis C virus infection among hemodialysis patients in the Middle-East: A systematic review and meta-analysis.

Authors:  Soheil Ashkani-Esfahani; Seyed Moayed Alavian; Mohammad Salehi-Marzijarani
Journal:  World J Gastroenterol       Date:  2017-01-07       Impact factor: 5.742

2.  Prevalence of occult hepatitis C virus among hemodialysis patients in Tanta university hospitals: a single-center study.

Authors:  Ghada Abdelmoemen; Samy Abdelkader Khodeir; Sabry Abou-Saif; Abdelrahman Kobtan; Sherief Abd-Elsalam
Journal:  Environ Sci Pollut Res Int       Date:  2017-12-06       Impact factor: 4.223

3.  Occult hepatitis C virus infection among hemodialysis patients.

Authors:  Guillermina Barril; Inmaculada Castillo; María Dolores Arenas; Mario Espinosa; Juan Garcia-Valdecasas; Nuria Garcia-Fernández; Emilio González-Parra; José María Alcazar; Carmen Sánchez; José Carlos Diez-Baylón; Pilar Martinez; Javier Bartolomé; Vicente Carreño
Journal:  J Am Soc Nephrol       Date:  2008-08-06       Impact factor: 10.121

4.  A shield against a monster: Hepatitis C in hemodialysis patients.

Authors:  Seyed-Moayed Alavian
Journal:  World J Gastroenterol       Date:  2009-02-14       Impact factor: 5.742

5.  Infection by the hepatitis C virus in chronic renal failure patients undergoing hemodialysis in Mato Grosso state, central Brazil: a cohort study.

Authors:  Marcelo A M Santos; Francisco J D Souto
Journal:  BMC Public Health       Date:  2007-03-12       Impact factor: 3.295

6.  Acute hepatitis C virus infection assessment among chronic hemodialysis patients in the Southwest Parana State, Brazil.

Authors:  Maricea Engel; Fernanda M Malta; Michele M S Gomes; Isabel M V G C Mello; João R R Pinho; Suzane K Ono-Nita; Flair J Carrilho
Journal:  BMC Public Health       Date:  2007-04-04       Impact factor: 3.295

7.  Re-infection following sustained virological response with a different hepatitis C virus genotype: implications for infection control policy.

Authors:  Michelle M O'Shaughnessy; John A O'Regan; Frank E Murray; Jeff A Connell; Margaret P Duffy; Veronica M Francis; Sharon Dwyer; Lelia M Thornton; Peter J Conlon
Journal:  Clin Kidney J       Date:  2012-04-18

Review 8.  Hepatitis C virus infection and dialysis: 2012 update.

Authors:  Fabrizio Fabrizi
Journal:  ISRN Nephrol       Date:  2012-12-17

Review 9.  Viral hepatitis in hemodialysis: An update.

Authors:  Bassam Bernieh
Journal:  J Transl Int Med       Date:  2015-09-30

10.  Evidence of association between hepatitis C virus genotype 2b and nosocomial transmissions in hemodialysis centers from southern Brazil.

Authors:  Naylê Maria Oliveira da Silva; Fabiana Nunes Germano; Raul Andres Mendoza-Sassi; Hector Nicolas Seuánez; Marcelo Alves Soares; Ana Maria Barral de Martinez
Journal:  Virol J       Date:  2013-05-29       Impact factor: 4.099

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.